Meeting News CoverageVideo

VIDEO: Long-term nivolumab therapy produces ‘exciting’ results in kidney cancer

The use of nivolumab improved 4- and 5-year overall survival three-fold in patients with kidney cancer, according to data presented at the ASCO Annual Meeting.

“That survival outcome is remarkable when you think about where kidney cancer was just 5 and 10 years ago, [when] the 5-year survival for patients at the frontline might have been 10% or so,” David F. McDermott, MD, leader of the kidney cancer program at the Dana-Farber / Harvard Cancer Center, told HemOnc Today. “Now we’re seeing a third of patients alive at 4 and 5 years who started treatment after failing prior treatment, meaning you couldn’t go on these phase 1 or 2 trials without having failed treatment so survival data was encouraging.”

In this video, McDermott discusses updated long-term survival results seen with the PD-1 inhibitor nivolumab (Opdivo, Bristol-Myers Squibb) in patients with metastatic kidney cancer.

McDermott highlights the occurrence of adverse events in both the long-term follow-up phase 1 and 2 studies and mentions that the majority of events occurred within the first 6 months of treatment.

“In fact, we didn’t see any adverse events beyond 30 months on either study, which was encouraging,” he said.   

In addition, McDermott discusses how there will be future studies to analyze if there are any clinical characteristics that may predict long-term benefit.

“Moving forward, this is obviously [a] fairly large group, about 200 patients, but ultimately we need to confirm these findings in a randomized trial – which hopefully the phase 3 trial will allow us to do,” he said.

The use of nivolumab improved 4- and 5-year overall survival three-fold in patients with kidney cancer, according to data presented at the ASCO Annual Meeting.

“That survival outcome is remarkable when you think about where kidney cancer was just 5 and 10 years ago, [when] the 5-year survival for patients at the frontline might have been 10% or so,” David F. McDermott, MD, leader of the kidney cancer program at the Dana-Farber / Harvard Cancer Center, told HemOnc Today. “Now we’re seeing a third of patients alive at 4 and 5 years who started treatment after failing prior treatment, meaning you couldn’t go on these phase 1 or 2 trials without having failed treatment so survival data was encouraging.”

In this video, McDermott discusses updated long-term survival results seen with the PD-1 inhibitor nivolumab (Opdivo, Bristol-Myers Squibb) in patients with metastatic kidney cancer.

McDermott highlights the occurrence of adverse events in both the long-term follow-up phase 1 and 2 studies and mentions that the majority of events occurred within the first 6 months of treatment.

“In fact, we didn’t see any adverse events beyond 30 months on either study, which was encouraging,” he said.   

In addition, McDermott discusses how there will be future studies to analyze if there are any clinical characteristics that may predict long-term benefit.

“Moving forward, this is obviously [a] fairly large group, about 200 patients, but ultimately we need to confirm these findings in a randomized trial – which hopefully the phase 3 trial will allow us to do,” he said.

    See more from ASCO Annual Meeting